Overview
- Parabilis priced an upsized offering of 33,500,000 shares at $20 per share, with a 30-day option for 5,025,000 additional shares.
- The company expects roughly $670 million in gross proceeds from the IPO and about $75 million from a concurrent private placement to Regeneron priced at $18 per share for 4,166,666 shares.
- Parabilis common stock is expected to begin trading on the Nasdaq Global Select Market under ticker PBLS on June 10, 2026, and the offering is targeted to close on or about June 11, 2026 subject to customary closing conditions.
- The IPO is led by Leerink Partners, BofA Securities, Evercore ISI and Guggenheim as active book-runners with LifeSci Capital as a passive manager, and all shares in the deal are being sold by Parabilis.
- Parabilis is a clinical-stage biotech developing Helicons™, stabilized helical peptides aimed at hard-to-drug proteins, and the company says the new capital will support its ongoing clinical programs and operations.